Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02468024 · ClinicalTrials.gov registry record · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
- 20
- Study locations
NCT02468024 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 272 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT02468024, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
- 20
- Study locations
Study Summary
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Conditions Studied
Interventions
- RADIATION Radiation therapy
- PROCEDURE Lung Surgery
Study Locations (20)
Colorado
- University of Colorado/Memorial - Aurora
- Penrose Cancer Center - Colorado Springs
Kentucky
- University of Kentucky Health Care - Lexington
- University of Louisville Physicians - Louisville
Maryland
- Luminis Health Research Institute - Annapolis
- University of Maryland Medical Center - Baltimore
Michigan
- Henry Ford Health System - Detroit
- Beaumont - Royal Oak
New York
- New York University Langone Medical Center - New York
- SUNY - Upsate Medical Centre - Syracuse
California
- UCSD - La Jolla
Florida
- Boca Raton Regional Hospital - Boca Raton
Georgia
- Curtis and Elizabeth Anderson Cancer - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2015-07 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02468024
The ClinicalTrials.gov registry entry for NCT02468024 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation therapy is the first listed.
NCT02468024 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Colorado, Kentucky, Maryland.
Frequently Asked Questions
What is clinical trial NCT02468024 about?
NCT02468024 is a clinical study titled "JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer". To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
What is the current status of trial NCT02468024?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2015-07. Estimated completion is 2028-12.
What conditions does trial NCT02468024 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02468024?
The interventions under investigation include: Radiation therapy (RADIATION), Lung Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02468024?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02468024 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.